LEA_2A: LEA, figure 2A

LEA_2AR Documentation

LEA, figure 2A

Description

Kaplan-Meier digitized data from LEA, figure 2A (PMID 25691671). A reported sample size of 374 for a primary endpoint of PFS in breast cancer.

Usage

LEA_2A

Format

A data frame of 374 observations and 3 variables:

time event time (in months)
event PFS event indicator (0: no event, 1: event)
arm treatment arms (et, et_b)

Source

Martín M, Loibl S, von Minckwitz G, et al. Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study. J Clin Oncol 2015; 33: 1045–52.

Examples

summary(LEA_2A)

kmplot(LEA_2A)

raredd/kmdata documentation built on June 15, 2025, 9:33 a.m.